Biotech investors faced a dense catalyst calendar on Tuesday, December 9, 2025, as new U.S. Food and Drug Administration (FDA) signals on cell and gene therapy, fresh designations in hematologic cancers and high‑impact clinical data from the American Society of Hematology (ASH) meeting collided with a wave of secondary offerings.
Despite a string of double‑digit movers, the sector finished in the red. The iShares Nasdaq Biotechnology ETF (IBB) closed around $167, down roughly 1.6% on the day, while the SPDR S&P Biotech ETF (XBI) slid about 1.8%. By contrast, the SPDR S&P 500 ETF (SPY) was essentially flat and the Invesco QQQ Trust (QQQ) added about 0.2%, underscoring a day of biotech underperformance against a steady broader market.
Sector snapshot: biotech lags as indices slip into the close
Biotech’s two key U.S. sector proxies both recorded a down session:
- IBB hovered near $167.3 at the close, down about 1.6% from Monday, after trading between roughly $167 and $171 intraday.
- XBI finished near $121.5, off about 1.8%, also closing at the low end of its daily range.
The modest pullback came despite ongoing enthusiasm around obesity drugs and hematology data out of ASH 2025, suggesting that heavy profit‑taking and fresh equity offerings weighed on high‑beta biotech names even as individual stories remained very active.
FDA news: RMAT designation, trial redesigns and tougher CAR‑T standards
Senti Bio wins RMAT for AML cell therapy SENTI‑202
Senti Biosciences reported that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI‑202, its off‑the‑shelf CAR‑NK cell therapy for relapsed or refractory acute myeloid leukemia (AML) and related hematologic malignancies.
New Phase 1 data from an ongoing trial showed:
- An overall response rate of 50% at the recommended Phase 2 dose (RP2D).
- Complete remission (CR) or CR with partial hematologic recovery in about 42% of patients at RP2D and close to 40% across the entire study population.
SENTI‑202 was detectable in peripheral blood in all participants, with pharmacokinetics in line with other allogeneic NK products.
Despite what would normally be considered very strong early efficacy for a difficult AML population, Senti’s shares were volatile, swinging intraday and ultimately ending down more than 30% around $1.57, reflecting profit‑taking after an earlier spike and the dilutive overhang typical of early‑stage cell therapy companies.
Praxis Precision Medicines and FDA streamline Elsunersen’s registrational path
Praxis Precision Medicines announced that following a Type C meeting, the FDA agreed to simplify and accelerate the registrational EMBRAVE3 trial of elsunersen (PRAX‑222) for early‑onset SCN2A developmental and epileptic encephalopathy (DEE). Key changes include:
- Converting EMBRAVE3 from a randomized, sham‑controlled design to a single‑arm, baseline‑controlled registrational study.
- Reducing target enrollment from 40 to 30 children.
- Ensuring all screened patients receive active treatment for 24 weeks before transitioning to an open‑label extension.
Elsunersen has already secured Orphan Drug and Rare Pediatric Disease designations in the U.S. and PRIME status in Europe. Praxis shares, which have had a strong run on earlier positive epilepsy and movement‑disorder data, traded lower by about 4–5% to roughly $258, likely reflecting expectations already embedded in the price rather than disappointment with today’s update.
FDA tightens expectations for CAR‑T approvals
In a widely watched move, the FDA signaled a higher evidentiary bar for future CAR‑T approvals. A Perspective article in the Journal of the American Medical Association by senior Center for Biologics Evaluation and Research leadership argued that:
- Traditional approvals should be based on randomized controlled trials, not single‑arm studies.
- Experimental CAR‑T products should be compared directly with the current standard of care, including already‑approved CAR‑T therapies.
- Single‑arm data may still justify accelerated approval, but sponsors will need randomized, controlled evidence to convert to full approval.
All seven CAR‑T therapies currently on the U.S. market were cleared largely on single‑arm data, making this a meaningful philosophical shift that could lengthen timelines and increase costs for cell‑therapy developers. Investors in companies such as Gilead and Arcellx, whose BCMA‑targeted CAR‑T anito‑cel is currently in a single‑arm Phase II registrational study, will be watching closely for any knock‑on regulatory impact.
Airiver Medical gains IDE approval for chronic rhinosinusitis device
On the device side, Airiver Medical said the FDA approved its Investigational Device Exemption (IDE) application for a drug‑coated balloon designed to treat chronic rhinosinusitis, enabling a pivotal trial to proceed in the U.S. While not a direct driver of biotech indices, the decision underscores continued FDA openness to interventional approaches that blend device engineering with localized drug delivery.
ASH 2025 hematology data: leukemia and myeloma names in focus
Terns Pharmaceuticals: “Unprecedented” CML data sends TERN higher
At the ASH annual meeting, Terns Pharmaceuticals showcased updated results from the Phase I CARDINAL trial of TERN‑701, an allosteric BCR‑ABL1 inhibitor for chronic myeloid leukemia (CML) patients previously treated with other tyrosine kinase inhibitors.
Key efficacy signals included:
- A 75% major molecular response (MMR) rate at week 24 among efficacy‑evaluable patients.
- Response rates more than double those reported for Novartis’ STAMP inhibitor Scemblix and other competitors in similar settings, according to analyst comparisons.
Terns’ stock climbed around 5–6% to roughly $42.5, after briefly trading above $45 intraday, extending a sharp multi‑day rally that has already repriced expectations for TERN‑701 as a potential best‑in‑class CML therapy.
Exicure rockets on Phase 2 multiple myeloma data
Exicure delivered one of the day’s biggest pops. The company reported positive topline results from a Phase 2 trial of burixafor in multiple myeloma, describing encouraging efficacy and safety signals in a difficult‑to‑treat setting.
Shares surged about 41% to the mid‑$7 range on heavy volume, reflecting renewed optimism that burixafor could carve out a role in combination regimens for hematologic malignancies.
Senti‑202 AML data adds to regulatory momentum
Senti’s SENTI‑202 results were another hematology highlight, with half of patients at the RP2D achieving clinical responses and more than 40% reaching complete remission or CR with partial hematologic recovery. Coupled with RMAT designation, the dataset strengthens the case for SENTI‑202 as a differentiated off‑the‑shelf cell therapy for AML, even if today’s stock reaction was muted to negative.
Lilly’s Jaypirca delivers strong front‑line CLL data
Eli Lilly released results from the Phase 3 BRUIN CLL‑313 trial evaluating its non‑covalent BTK inhibitor Jaypirca (pirtobrutinib) in treatment‑naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) without 17p deletions.
Pirtobrutinib:
- Reduced the risk of disease progression or death by about 80% compared with bendamustine plus rituximab (BR), the standard chemo‑immunotherapy regimen.
- Showed consistent benefits across pre‑specified subgroups, with overall survival trends favoring Jaypirca, although OS data remain immature.
Lilly has begun submitting the BRUIN CLL‑313 and CLL‑314 data to regulators in a bid to move Jaypirca into earlier‑line CLL settings. The stock, however, slipped about 1.7% to around $981, reflecting high expectations already baked into Lilly’s multi‑franchise valuation rather than disappointment with the data.
Obesity and metabolic programs: Wave extends GLP‑1 enthusiasm
While Monday’s dramatic move in Structure Therapeutics — which nearly doubled after its oral GLP‑1 aleniglipron produced more than 11% placebo‑adjusted weight loss at 36 weeks in a Phase II trial — technically belongs to the prior session, its echo could be felt across obesity‑focused biotech on Tuesday.
Wave Life Sciences rallies on WVE‑007 body‑composition data
Wave Life Sciences extended the GLP‑1 momentum with new results from the lowest therapeutic cohort of the INLIGHT trial of WVE‑007, its investigational obesity therapy. In a single‑dose 240 mg cohort, Wave reported at three months:
- A 9.4% reduction in visceral fat.
- A 4.5% reduction in total body fat.
- A 3.2% increase in lean mass.
Investors cheered the body‑composition profile and a wave of analyst upgrades, sending WVE shares up around 15–16% to roughly $21.4, a new 52‑week high.
The company simultaneously launched a $250 million underwritten public offering of ordinary shares and pre‑funded warrants, with up to a 15% underwriter option — a substantial raise that will help fund further obesity and RNA‑targeting programs while modestly diluting existing holders.
Capital raises: Denali, Vera and others tap receptive markets
A key theme of the day was biotech balance‑sheet repair, as several companies moved quickly to capitalize on recent share‑price strength.
- Denali Therapeutics unveiled plans for a $200 million offering of common stock and pre‑funded warrants, with underwriters granted a 30‑day option for up to an additional $30 million. Denali framed the raise as support for its neurodegeneration pipeline. The stock finished roughly flat near $19.7, suggesting investors had largely anticipated a financing.
- Vera Therapeutics filed to sell $200 million of Class A common stock, also accompanied by a potential 15% underwriter option. Proceeds are expected to support development of atacicept in IgA nephropathy and other autoimmune indications. Vera’s shares slipped less than 1% to about $44.7, a relatively modest reaction given the deal size.
Together with Wave’s $250 million transaction, these offerings underscore that public capital remains available for late‑stage or high‑momentum pipelines, though the associated overhang contributed to index‑level weakness.
What today’s moves mean for biotech investors
Tuesday’s tape reinforced several broader themes for the biotech space:
- Regulation is getting more demanding, especially in cell therapy. The FDA’s clear preference for randomized trials in CAR‑T could lengthen timelines and raise trial costs but should also reduce uncertainty around future approvals and payer adoption.
- High‑quality efficacy still gets rewarded. Exicure’s 40%+ surge on multiple myeloma data, Terns’ continued strength on best‑in‑class CML responses and Senti’s promising AML data all show that convincing clinical signals can cut through broader sector softness.
- Obesity remains a central growth narrative. Structure and Wave are the latest proof that credible oral or next‑generation obesity mechanisms can dramatically re‑rate small and mid‑cap biotechs, even amid intense competition from big pharma incumbents.
- Financing risk hasn’t disappeared. The steady parade of secondary offerings from Denali, Vera, Wave and others signals that even strong stories will use rallies to bolster cash balances, a dynamic that can pressure sector ETFs in the short term.
For now, the biotech complex sits in a familiar position: the index level masks considerable dispersion, with regulatory headlines and clinical data separating future winners from also‑rans even on a down day for the group.
